OncoMatch/Clinical Trials/NCT05393804
A Study of Whether Ide-cel (bb2121) Can Be Made From People With Multiple Myeloma Who Have Had a Hematopoietic Cell Transplant
Is NCT05393804 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Ide-cel (bb2121) for multiple myeloma.
Treatment: Ide-cel (bb2121) — The purpose of this study is to see if the quality of T cells used to create ide-cel (bb2121) affects how ide-cel prevents cancer from coming back in people with relapsed or refractory multiple myeloma (MM), and who have had a hematopoietic cell transplant.
Check if I qualifyExtracted eligibility criteria
Cancer type
Multiple Myeloma
Prior therapy
Must have received: immunomodulatory drug
having been exposed to an IMID
Must have received: proteasome inhibitor
having been exposed to a PI
Must have received: CD38 monoclonal antibody
having been exposed to a CD38 monoclonal antibody
Must have received: hematopoietic cell transplant (autologous, allogeneic)
salvage high dose melphalan autoHCT done within the prior 2 - 6 months; have undergone an allo HCT for RRMM at any time in their history
Cannot have received: organ transplant requiring systemic immunosuppressive therapy
Prior organ transplant requiring systemic immunosuppressive therapy
Lab requirements
Blood counts
ANC ≥ 1,000/mm^3 without filgrastim use in the prior 14 days; Hemoglobin ≥ 8 g/dL (without red blood cell transfusion in the previous 7 days); Platelet count ≥ 50,000/mm^3 (transfusion allowed)
Kidney function
Creatinine Clearance (CrCl) ≥ 45 mL/min, measured or estimated by Cockcroft-Gault equation
Liver function
Serum AST and ALT ≤ 2.5 × ULN; Serum total bilirubin ≤ 2 × ULN (Gilbert's disease exception); INR or PTT ≤ 1.5 x ULN
Cardiac function
left ventricular ejection fraction ≥ 45% by echocardiogram (ECHO) or multigated acquisition scan (MUGA)
Serum AST and ALT ≤ 2.5 × ULN; Serum total bilirubin ≤ 2 × ULN. Patients who have been diagnosed with Gilbert's disease are permitted to exceed the defined bilirubin value of 2 x ULN; INR or PTT ≤ 1.5 x ULN; Creatinine Clearance (CrCl) ≥ 45 mL/min, measured or estimated by Cockcroft-Gault equation; ANC ≥ 1,000/mm^3 without filgrastim use in the prior 14 days; Hemoglobin ≥ 8 g/dL (without red blood cell transfusion in the previous 7 days); Platelet count ≥ 50,000/mm^3 (transfusion allowed); left ventricular ejection fraction ≥ 45% by echocardiogram (ECHO) or multigated acquisition scan (MUGA)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) · Basking Ridge, New Jersey
- Memorial Sloan Kettering Monmouth (Limited Protocol Activities) · Middletown, New Jersey
- Memorial Sloan Kettering Bergen (Limited Protocol Activities) · Montvale, New Jersey
- Memorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities) · Commack, New York
- Memorial Sloan Kettering Westchester (Limited Protocol Activities) · Harrison, New York
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify